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Background: Hypophosphatasia (HPP) is a rare inborn error of metabolism that results from a dysfunctional
tissue non-specific alkaline phosphatase enzyme (TNSALP). Although genotype-phenotype correlations have
been described in HPP patients, only sparse information is currently available on the genetics of mild type HPP.
Methods: We investigated 5 Japanese patients from 3 families with mild HPP (patients 1 and 2 are siblings;
patient 4 is a daughter of patient 5) who were referred to Fujita Health University due to the premature loss of
deciduous teeth. Physical and dental examinations, and blood, urine and bone density tests were conducted.
Genetic analysis of the ALPL gene was performed in all patients with their informed consent.
Results: After a detailed interview and examination, we found characteristic symptoms of HPP in some of the
study cases. Mobile teeth or the loss of permanent teeth were observed in 2 patients, and 3 out of 5 patients had a
history of asthma. The serum ALP levels of all patients were 30% below the lower limit of the age equivalent
normal range. ALPL gene analysis revealed compound heterozygous mutations, including Ile395Val and
Leu520Argfs in family 1, Val95Met and Gly491Arg in family 2, and a dominant missense mutation (Gly456Arg)
in family 3. The 3D-modeling of human TNSALP revealed three mutations (Val95Met, Ile395Val and Gly456Arg)
at the homodimer interface. Severe collisions between the side chains were predicted for the Gly456Arg variant.
Discussion: One of the characteristic findings of this present study was a high prevalence of coexisting asthma
and a high level serum IgE level. These characteristics may account for the fragility of tracheal tissues and a
predisposition to asthma in patients with mild HPP. The genotypes of the five mild HPP patients in our present
study series included 1) compound heterozygous for severe and hypomorphic mutations, and 2) dominant-
negative mutations. All of these mutations were at the homodimer interface, but only the dominant-negative
mutation was predicted to cause a severe collision effect between the side chains. This may account for varying
mechanisms leading to different effects on TNSALP function.
1. Objective
Hypophosphatasia (HPP) is an inherited disorder characterized by
defective bone and tooth mineralization, and a deficiency in tissue-non-
specific alkaline phosphatase isoenzyme (TNSALP) activity [1]. The
incidence of this disorder is not accurately known, but the birth pre-
valence of the most severe forms of HPP, i.e. perinatal and infantile, is
estimated at 1:100,000 [2]. An estimate of 1:6370 has been suggested
previously for less severe forms of HPP using molecular data [3].
TNSALP is a phosphomonoesterase of 507 residues that is anchored
at its carboxyl terminus to the plasma membrane by a
phosphatidylinositol-glycan moiety. This enzyme is physiologically
active in its dimeric form and cleaves the extracellular substrates pyr-
idoxal-5′-phosphate (PLP), phosphoethanolamine (PEA) and inorganic
pyrophosphates (PPi) [1]. Low TNSALP activity has impacts on multiple
systems, including the respiratory, central nervous, renal, muscu-
loskeletal, and immune systems, and on dental structures [4].
HPP is caused by mutations in the liver/bone/kidney alkaline
phosphatase (ALPL) gene encoding TNSALP [5,6]. To date, 390 muta-
tions have been identified in ALPL that show an association with HPP.
(http://www.sesep.uvsq.fr/03_hypo_mutations.php). HPP symptoms
are highly variable in terms of their clinical expression, and six clinical
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forms are currently recognized. These are based on the age at diagnosis
and the severity of disease features including lethal perinatal, benign
perinatal, infantile, childhood, adult, and odontohypophosphatasia
(odonto-HPP) [6]. Enzyme replacement therapy (ERT) has recently
been reported to be efficient and improve patient outcomes even in
cases of life-threatening forms of HPP [7]. Although some genotype/
phenotype correlations have been described for a portion of the ALPL
mutations, the mechanisms underlying HPP remain incompletely un-
derstood, particularly in the mild forms of this disorder.
In our present study, we analyzed the clinical and genetic aspects of
a small series of Japanese patients with mild HPP.
2. Material and methods
2.1. Informed consent and ethical approval
Informed consent was obtained from each patient and/or their fa-
mily. The study protocol was approved by the Ethical Review Board for
Human Genome Studies at Fujita Health University.
2.2. Clinical survey of mild HPP patients
In our present study, mild HPP refers to childhood and adult HPP,
odontohypophosphatasia, and perinatal benign HPP. Severe HPP de-
notes the perinatal and infantile forms. We reviewed the medical charts
of 5 patients from 3 families who presented with mild HPP and had
sufficient follow-up data. Patients 1 and 2 are siblings, and patient 4 is
the daughter of patient 5. All of these cases had been referred to Fujita
Health University Hospital for a detailed medical examination due to
the premature loss of deciduous teeth. Our review of these cases in-
cluded all available data from the physical examinations and medical
care provided at the Fujita Health University Hospital.
All patients had a diagnosis of HPP clinically, biochemically, and
genetically. The diagnosis of HPP required that all of the following
criteria be met at the first admission: 1) a medical history or physical
examination consistent with one or more dento-osseous complication(s)
of HPP; 2) no evidence of any other condition that could cause the early
loss of primary teeth; and 3) a serum ALP activity level below the age-
matched reference ranges [8]. Physical and dental histories were re-
corded through a diagnostic interview process. Dental examinations
were carried out at Department of Plastic Surgery, Division of Pediatric
Dentistry & Orthodontics, Fujita Health University of Medicine. Clinical
signs and symptoms were evaluated based upon a physical and oral
examination, and the available medical or dental records. Biochemical
and radiographic tests were performed at diagnosis. The serum ALP,
PLP, Ca, phosphorus, parathyroid hormone (PTH), total serum IgE and
1,25-OH vitamin D levels, and the urine PEA levels on a spot urine test,
were evaluated in all patients. The reference values for serum ALP,
serum PLP/PL and urine PEA were obtained from Tanaka et al. [9],
Akiyama et al. [10] and SRL Inc., respectively. A high total serum IgE
was defined as a level higher than the adult standard value (> 250 IU/
mL). Short stature was defined as a height below -2SD. Non atopy was
defined as no evidence of pruritic skin, including no reporting by a
parent of any rubbing or scratching by the child [11].
Bone mineral density (BMD) was measured at the level of the
lumbar spine (L2-L4) using dual-energy X-ray absorptiometry. BMD Z-
scores were calculated using data from a general population of
Japanese children and adolescents (BMD of the lumber spine and total
body mass) after adjusting for age. However, because these prior data
do not include children under 6 years of age, the Z-scores were calcu-
lated for our current study patients 1 and 2 only.
2.3. ALPL gene analysis
ALPL gene analysis was performed with informed consent. DNA was
extracted from peripheral blood samples and sequenced using the
Sanger method to screen for genetic variations at the nucleotide level
throughout all coding exons of the ALPL gene. We used the UCSC
genome browser (http://genome-asia.ucsc.edu/human GRCh38/hg38)
as the human genome assembly. PCR was carried out in a 10 μL volume
containing 5.7 μL of distilled water, 2 μL of 5☓PrimeSTAR GXL buffer
(TaKaRa, Japan), 0.2 μL of each primer (10 μM), 0.1 μL of PrimeSTAR
GXL DNA polymerase (TaKaRa, Japan), and 1 μL of template DNA
(20 ng/μL). The primer sequences are listed in the Online
Supplementary Table. PCR amplifications were performed using a DNA
thermal cycler (Applied Biosystems) under the following cycling con-
ditions: initial denaturation at 94 °C for 2.5min followed by 35 cycles at
98 °C for 10s, 60 °C for 15 s and 68 °C for 45 s. The PCR products were
sequenced using a standard Sanger method. The ALPL sequence from
the HPP patients was compared to control subjects and the reference
ALPL sequence (Ref Seq NM_000478.5). Allele frequencies were in-
vestigated via gnomAD browser beta (http://gnomad.broadinstitute.
org/). In silico analysis was performed using PolyPhen and SIFT.
2.4. 3D-modeling
A 3D model of the TNSALP molecule was previously constructed
using the homology between TNAP and human placental alkaline
phosphatase, which has a determined crystal structure. The locations of
the mutations were determined using the UCSF Chimera (www.cgl.ucsf.
edu/chimera).
3. Results
3.1. Clinical evaluations
The chief complaints at diagnosis were premature loss of deciduous
teeth in patients 1 to 4 and permanent teeth loss in patient 5. The dental
features of these cases are summarized in Table 1. All of the study
patients had premature loss of their anterior deciduous teeth and
atrophy of the alveolar bone. Permanent tooth loss was found in patient
5 only, but the mobility of permanent teeth was also evident in patient
1. Elongation of teeth and enamel hypoplasia were observed in 2 and 3
of the 5 patients, respectively. The results of biochemical of
Table 1
Dental features of the study patients.
Dental features Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Age at diagnosis 9 y 7 y 1 y 4 y 39 y
Premature loss of anterior deciduous teeth + + + + +
Premature loss of posterior deciduous teeth + Mobility − − +
Loss of permanent teeth Mobility − -a -a +, Mobility
Delay of eruption − − − − −
Atrophy of alveolar bone + + + + +
Elongation of teeth − + − − +
Enamel hypoplasia + − + + −
a Deciduous dentition.
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radiographic testing, and the clinical findings other than the dental
features at diagnosis, for all 5 study patients are presented in Table 2.
Our present cases had been referred to our hospital in the first instance
due to a single symptom i.e. the premature loss of deciduous teeth.
After a detailed interview and examination however, other character-
istic symptoms, and biochemical and radiographic findings, became
evident as follows: dysphagia (1/5), headache (1/5), muscle ache (1/5),
bone fractures (2/5), asthma (3/5), low serum ALP levels (5/5), high
serum PLP/PL (5/5), high urine PEA levels (5/5), high serum IgE (4/5),
flared metaphyses (1/5), and low Z-score BMD (2/2). All of our study
patients showed serum ALP levels at> 30% below the lower limit of
the age equivalent normal range. The serum PLP/PL and urine PEA
levels were higher in all of our HPP patients compared to the control
subjects. The BMD was measured in four patients, of whom two patients
showed a low Z-score but this could not be calculated in the remaining
two cases because their age were under 6.
3.2. Gene analysis
The results of our ALPL mutation sequencing analyses are presented
in Table 3. The clinical forms of the genotypes were described pre-
viously [12–15]. The three families in our current series all harbored
different mutations that are rare within the general population, and had
a minor allele frequency ranging from completely unreported to
0.00003716 (gnomAD browser beta). Family 1 (patients 1 and 2)
members carried the compound heterozygous ALPL variants
c.1183A>G (p.Ile395Val) and c.1559delT (p.Leu520Argfs). The
c.1183A>G (p.Ile395Val) mutation was reported previously to result
in a prenatal benign phenotype as the gene product still possessed re-
sidual ALP activity of 19.1% [16]. The c.1559delT (p.Leu520Argfs)
variant is a null mutation that was previously reported to be common in
Japanese severe HPP patients [17].
Family 2 (patient 3) was found to harbor compound heterozygous
variants including c.283G>A (p.Val95Met) and c.1471G>A
(p.Gly491Arg). Mutation c.283G>A (p.Val95Met) was registered
previously in a public database (Institute of Human Genetics, University
Of Wurzburg), and classified as “with likely pathogenic” in ClinVar, but
no clinical information has been reported to date for this variation.
Analysis of the Val95Met substitution using SIFT and PolyPhen pre-
diction software indicated that this mutation was ‘tolerable’ and ‘pos-
sibly damaging’, with scores of 0.12 and 0.897, respectively. In con-
trast, c.1471G>A (p.Gly491Arg) is reported to be a severe perinatal
phenotype mutation [14]. These data suggest that the c.1471G>A
(p.Gly491Arg) mutation may be null whereas the gene product har-
boring the c.283G>A (p.Val95Met) variation may still possess residual
enzymatic activity.
Table 2
Clinical, biochemical and radiographic data for the study patients. N/A, not available. Reference values: Serum ALP from Tanaka et al. [9]; Serum PLP and PL from
Akiyama et al. [8]; urine PEA from SRL Inc. For serum ALP, reference values are shown for patients over 20 years of age. For serum PLP and PL, reference values for
7–17 year-old patients are shown.
Patient ID Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Age 10 8 1 4 39
Gender Female Male Female Female Female
Biochemical test
Ca (mg/dl) 9.7 (Reference: 8.7–10.3) 9.8 (8.7–10.3) 11.1 (8.7–10.3) 10.4 (8.7–10.3) 9.7 (8.7–10.3)
Phosphorus (mg/dl) 5.3 (2.5–4.7) 5.9 (2.5–4.7) 7.5 (2.5–4.7) 4.9 (2.5–4.7) 4.3 (2.5–4.7)
ALP (U/L) 228 (470–1450) 245 (450–1300) 155 (395–1289) 286 (430–1150) 50 (120–340)
PTH (pg/ml) 31 (15–65) 27 (15–65) 8 (15–65) 21 (15–65) 32 (15–65)
1,25-OH vitD (pg/ml) 62.2 (20–70) 58.1 (20–70) 88.3 (20–70) 61.2 (20–70) 57.2 (20–60)
PLP (pyridoxal-5′-phosphate)(nmol/L) 469.9 (14.5–57.3) 322.5 (14.5–57.3) 375.2 (16.2–57.4) 325.9 (16.2–57.4) 89.9 (14.5–57.3)
PL (pyridoxal)(nmol/L) 39.9 (7.4–17.7) 28.8 (7.4–17.7) 27.2 (8.8–28.0) 43.8 (8.8–28.0) 6.7 (7.4–17.7)
PLP/PL 11.8 11.2 13.8 7.4 13.3
Total IgE (IU/ml) 638.4 349.5 267.5 1099 17.1
Urine PEA (μmol/g Cr) 480.1 (39.4–93.5) 720.6 (29.1–75.6) 662.7 (39.4–93.5) 507.7 (39.4–93.5) 274.7 (39.4–93.5)
Clinical findings without dental features
Shortening or deformity of the extremities − − − − −
Bone fractures (NO.) 1 0 0 0 1
Part of fractures Forearm Right shoulder
Seizure − − − − −
Enlargement of the anterior fontanelle − − − − −
Renal calcification − − − − −
Stature (cm) 130 (−1.4SD) 123 (−0.2SD) 71.5 (−1.9SD) 100.4 (−0.85SD) 148.1 (−1.96SD)
Body weight (kg) 28.8 (−0.7SD) 23.9 (−0.1SD) 8.29 (−1.9SD) 15.5 (−0.9SD) 35.9
Deafness − − − − −
Asthma + + + − −
Atopy − − − − −
Muscle ache − + − − −
Dysphagia − − + − −
Other symptom − − − − Headache
Radiographic findings
Hypomineralisation − − − − −
Deformity of long bones − − − − −
Flared metaphyses − − + − −
Narrow thorax − − − − −
Bone mineral density (g/cm2) 0.644 (Z-score− 1.2) 0.551 (Z-score− 1.8) 0.298 0.395 N/A
Birth
Gestational age 39w5d 38w0d 38w2d 39w6d N/A
Birth weight (g) 2786 (−0.5SD) 2770 (−0.4SD) 2405 (−1.1SD) 2538 (−1.4SD) N/A
Birth stature (cm) 47 (−1.2SD) 48.5 (0.2SD) 48 cm (−0.2SD) 49 (−0.2SD) N/A
Birth head circumference (cm) 30 (−2.5SD) 33 (0.0SD) N/A 31.4 (−1.5SD) N/A
Birth chest circumference (cm) 31 31 N/A 30 N/A
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Family 3 (patients 4 and 5) had only one heterozygous mutation,
c.1366G>A (p.Gly456Arg), which had been initially reported as one
of the compound heterozygous mutations in the infantile form of HPP
[15], Furthermore, a recent study using transfection experiments has
indicated that this mutation has a dominant-negative effect [18].
3.3. 3D-modeling
The locations of the identified mutated residues in the 3D structures
of human TNSALP are presented in Fig. 1. In contrast to the severe
Gly491Arg mutation located at the surface of this protein, the three
mutations that characterized the mild HPP cases in our present study
(Val95Met, Ile395Val and Gly456Arg) were all localized at the homo-
dimer interface. Severe collisions between the side chains were pre-
dicted in the Gly456Arg variant (Fig. 2a), whereas a mild only and no
effect were predicted for the Val95Met and Ile395Val mutations, re-
spectively (Fig. 2b, c).
4. Discussion
One of the characteristic findings in our present study series of 5
patients was the high percentage of coexisting asthma (3/5) as well as
high level serum IgE (4/5). In addition, 3 out of the 4 patients with a
high serum IgE had asthma. Tracheomalacia is a known symptom of
perinatal lethal HPP [5] but the frequency of other clinical conditions
associated with wheezing in these cases, such as asthma and the serum
IgE level, have remained unknown. Although we examined only a very
small cohort of patients in our present study, more than half of these
cases showed a past or current medical history of asthma and a high
serum IgE. These characteristics may account for the fragility of tra-
cheal tissues and a predisposition to asthma in mild HPP patients. Al-
though the treatment approaches for HPP have historically been sup-
portive in nature, enzyme replacement therapy (ERT) has recently
become available for these patients using asfotase alfa (Strensiq™), a
bone-targeting recombinant alkaline phosphatase [19]. This enzyme
has produced beneficial effects in terms of survival and function in HPP
patients [20,21]. However the selection of appropriate candidates for
this ERT has remained challenging when the condition is not life-
threatening [19]. The loss of permanent teeth has a detrimental impact
on quality of life but no study has demonstrated the effectiveness of an
early ERT in preventing this outcome in mild HPP. Further studies are
needed to assess the efficacy of these therapies.
Our present mutational analysis identified compound heterozygous
mutations in family 1, i.e. one obvious loss-of-function mutation
(1559delT) and one variant that still possessed some residual enzymatic
activity (Ile395Val). In family 2, one identified mutation (Gly491Arg)
was previously described as severe, and another (Val95Met) to have
only weak effects, by in silico functional data. Since the phenotype of
patient 3 in this family was mild, it is possible that Val95Met may
possess some residual ALP activity in this case. Family 3 harbored only
one mutation (Gly456Arg) with an autosomal dominant transmission.
This variant was reported previously to have a dominant-negative effect
Table 3
Genotype-phenotype correlations within the HPP families examined in this study.
Mode of inheritance Family 1 (patients 1 and 2) Family 2 (patient 3) Family 3 (patients 4 and 5)
AR AR AR AD
Genotype c.1183A>G(p.Ile395Val) c.1559delT(p.Leu520Argfs) c.283G>A(p.Val95Met) c.1471G>A(:p.Gly491Arg) c.1366G>A(p.Gly456Arg)
In silico function (PolyPhen) 0.535 0.897 1 0.945
In silico function (SIFT) 0.08 0.12 0 0
Clinical form of the
genotype
Prenatal benign Infantile Unknown Perinatal Infantile
Previous report Wenkert et al. 2011 Orimo et al. 1994 Novel Mornet et al. 1998 Ozono et al. 1996
Prevalence (% east Asia/
total)
0.002031/ 0 0.0008803/ 0.01187 0.003716/ 0 0/0 0/0
ACMG evaluation Likely pathogenic Pathogenic Likely pathogenic Likely pathogenic Pathogenic
Position in the 3D structure Interface of homodimer Unclear lesion Interface of homodimer Surface of protein Interface of homodimer
Fig. 1. 3D strand view of the human TNSALP pro-
tein. The two monomers are denoted by Chain A and
Chain B. The three amino-acid residues that were
found to be mutated in our mild HPP cases (G456R,
V95M, I395V) are localized on the homodimer in-
terface. Gly491Arg is located on the surface of the
protein. Leu520Argfs is located within the region
where the 3D structure has not yet been clearly de-
termined.
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in vitro, although our present study is the first to clinically demonstrate
Gly456Arg as autosomal dominant. Hence, the genotype of mild HPP
can be classified as either 1) compound heterozygous for a severe and
hypomorphic mutation; or 2) dominant-negative mutations. In family
1, two patients harboring the same mutations seemed to manifest a
similar degree of disease severity. In family 3, patient 5 is the mother of
patient 4 harboring the same mutation and had similar symptoms in her
own childhood. Hence, a genotype-phenotype correlation was present
in our current cases. Genetic testing for these genotypes will assist with
genetic counseling.
The mechanisms underlying the effects of the mutations in our
current study series, i.e. the reasons for a dominant or recessive effect,
are still unclear. However, interactions between the monomers of the
dimeric TNSALP protein structure are likely to be involved [22].
TNSALP has five regions (the active site and its vicinity, the active site
valley, the homodimer interface, the crown domain, and the calcium-
binding domain), which are crucial for enzyme function and bone mi-
neralization [23]. It was previously reported that the TNSALP muta-
tions identified to date with a dominant effect are restricted to three
regions of the protein: the active site, homodimer and crown domain.
However the difference between the standard recessive mutation and
these dominant mutations is still unknown. A prevailing hypothesis is
that the dominant-negative effect may be due to the inhibition of the
wild-type monomer by a mutated monomer in the heterodimer, or the
sequestration of the wild-type protein by a mutant product in the Golgi
apparatus that prevents it from being transported to the membrane
[24]. In our current analysis, three of the identified mutations were
located at the homodimer interface, but the Gly456Arg mutation
showing a dominant-negative effect produced the most severe change
in 3-D modeling. TNSALP Gly456Arg variants may maintain monomer
interactions and might directly affect the enzymatic activity of dimers,
including those harboring mutations, whilst the dimers from normal
monomers would maintain small amounts of enzymatic activity. In
contrast, the dimers of the proteins containing the hypomorphic mu-
tations identified in families 1 and 2 (Ile395Val, Val95Met) could
maintain low levels of enzymatic activity because of the lesser impact of
these variations compared to Gly456Arg. Future investigations of the
differences in the 3D structures of TNSALP variants may reveal the
precise mechanisms underlying dominant-negative and recessive but
weak mutation effects.
Ethics approval and consent to participate
All procedures in this study were conducted in accordance with the
ethical standards of the responsible committee on human experi-
mentation (institutional and national) and with the Helsinki
Declaration of 1975, as revised in 2005(5).
Consent for publication
Written informed consent to publish medical information and
images was obtained from all patients and/or their family reported in
this publication.
Fig. 2. Structural models of the human TNSALP protein. (a) Gly456 is located at the homodimer interface. Severe collisions between the side chains occur in the case
of Gly456Arg (green).
(b) Val95 is located at the homodimer interface. Mild collisions occur in the case of Val95Met (green).
(c) Ile395 is located at the homodimer interface. No significant changes occur in the case of Ile395Val (green). (For interpretation of the references to colour in this
figure legend, the reader is referred to the web version of this article.)
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